Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Afghan Bubba Kush is a pharmaceutical-grade medical cannabis flower product distributed by Cannamedical Pharma, a German company specializing in medicinal cannabis. Classified as a hybrid strain, it features a very high delta-9-tetrahydrocannabinol (THC) content of approximately 31.30% and a low cannabidiol (CBD) content of less than 1%. The product is a botanical preparation of dried cannabis flowers intended for the management of various symptoms through the interaction of its constituent cannabinoids with the human endocannabinoid system. It is primarily prescribed in Germany for conditions where medical cannabis is indicated, such as chronic pain or spasticity, and is dispensed exclusively through pharmacies for administration via inhalation or oral routes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Afghan Bubba Kush.